Revolution Medicines (RVMDW) Net Equity Issued and Repurchased (2019 - 2026)

Revolution Medicines' Net Equity Issued and Repurchased history runs 7 years deep, the most recent figure standing at $141.9 million for Q1 2026.

• In Q1 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $141.9 million; the TTM figure through Mar 2026 stood at $201.4 million (changed N/A YoY), while the FY2025 annual figure was $347.9 million, up 484.71% from the prior year.
• Net Equity Issued and Repurchased for Q1 2026 stood at $141.9 million, up from $59.5 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $323.7 million in Q1 2023, with the low at $59.5 million in Q4 2024.
• The 4-year median for Net Equity Issued and Repurchased is $141.9 million (2026), against an average of $167.1 million.